Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment

Официальное название

Using Mathematical Quantification of Limb and Eye Movements of Parkinson's Disease Patients As a Biomarker for Classification and Prediction of Disease State and Response to Treatment

Обзор

This is a three-armed open investigational study that aims to differentiate, quantify, and categorize abnormal eye movements and upper limbs movements in patients with Parkinson's disease. The study is using investigational non-invasive devices for that reason including ANLIVA® Hand Movement and ANLIVA® Eye Movement.

Подробное описание

To evaluate performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras in subjects with Parkinson's disease.

A clinical investigator will be capturing data from the clinical encounter completed by default the same day in addition to other clinical questionnaires subjects will be filling themselves. A percentage of subjects will be asked prior to their arrival to be part of a subset study called OFF/ON study, where they will be asked not to take their IPD oral home medications prior to arrival. Both study procedure elements will be performed at the beginning of the evaluation and 60 minutes after taking their medication. There is also a longitudinal study part, where a percentage of the subjects will be asked to visit the clinic with 6 months interval, up to 4 times, including the first visit. There will be a percentage of approached subjects that belong to the category of Essential Tremor (ET) and Healthy control (HC) used for comparison purposes. ET and HC subjects will undergo the same recruitment and testing process.

Вмешательства

• Препарат 150% of their routine home dopaminergic medications dose right in the clinic
  IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar
• Устройство Evaluation of mathematical models
  Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras

Первичные конечные точки

• Quantification of current IPD motor symptoms using kinetic tremor and Dyskinesia test [Срок оценки: Day 1]

Вторичные конечные точки (2)

• Quantification of current IPD motor symptoms using rest tremor and postural tremor test [Срок оценки: Day 1]
• Classification between Dyskinesia or kinetic tremor [Срок оценки: Day 1]

Критерии участия

Критерии включения

For inclusion in the investigation, the subjects must fulfil all the below criteria prior to enrolment:

• Subjects already diagnosed with Idiopathic Parkinson's Disease (IPD)
• or subjects already diagnosed with Essential tremor (ET)
• or subjects who are healthy controls (HC) and are not diagnosed with IPD or ET
• Able to understand and sign the informed consent form.

Критерии исключения

Subjects that meet any of the below criteria will be excluded:

• Not able to sign the informed consent form
• Below 18 years of age
• Diagnosed with movement disorder other than IPD or ET that might interfere with hand movements or eye movements (tics, myoclonus, chorea, dystonia, etc)
• Has parkinsonism not due to IPD (drug induced, functional, vascular, etc)
• Visual or physical limitations that prevent the subject from performing the baseline eye study requirements
• Being involved in the planning and conduct of the clinical investigation (applies to all sponsor management staff, investigational staff and third-party vendors as applicable)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Диагностика

Центры проведения

США · 1 центр

• Dartmouth Hitchcock medical center — Manchester

Идентификаторы

NCT: NCT06586320 · STUS-001 · STUDY02002335

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗